Ra Medical Systems completed its previously announced stock-for-stock merger with Catheter Precision, a company focused on the cardiac electrophysiology market. David Jenkins, founder and CEO of Catheter Precision, has joined Ra Medical’s board of directors as executive chairman. Catheter Precision CFO James Caruso will also join the board. Completion of the merger process concludes a series of events dating to last summer. Catheter Precision is now a wholly owned subsidiary of Ra Medical. Ra Medical manufactures the DABRA excimer laser and catheters for the treatment of certain vascular diseases. Catheter Precision’s lead product, VIVO (View Into Ventricular Onset), is an FDA-cleared and CE mark product that uses noninvasive inputs to locate the origin of ventricular arrhythmias. VIVO has been used in more than 800 procedures in U.S. and European hospitals under a limited commercial launch in the third quarter of 2021. Preparations are underway for a full commercial launch in the first quarter of 2023. Catheter Precision’s product portfolio also includes the Amigo, a robotic arm that serves as a catheter control device. Catheter Precision is developing a third product, anticipated to be released in 2023, which is a device to assist in the closure of the percutaneous insertion site used in minimally invasive procedures, such as catheter ablation.